casino777gratisspins| Puli Pharmaceutical: Subsidiary Bilastine orally disintegrating tablets obtained clinical trial approval

News summary

[Pulastin Pharmaceutical: Subsidiary Bilastine Orally Disintegrating Tablets Obtained Clinical Trial Approval] Securities Times e Company News, Pulastin Pharmaceutical (300630) announced on the evening of May 22 that its subsidiary Zhejiang Pulastin Pharmaceutical Co., Ltd. received recentlycasino777gratisspinsReviewed the clinical application of bilastine orally disintegrating tablets issued by the State Food and Drug Administrationcasino777gratisspins...

Newsletter text

[Pulastin Pharmaceutical: Subsidiary Bilastine Orally Disintegrating Tablets Obtained Clinical Trial Approval] Securities Times e Company News, Pulastin Pharmaceutical (300630) announced on the evening of May 22 that the company's subsidiary Zhejiang Pulastin Pharmaceutical Co., Ltd. has recently received The approval notice for the clinical trial of Bilastin Orally Disintegrating Tablets issued by the State Food and Drug Administration, which is suitable for symptomatic treatment of urticaria in children aged 6 - 11 and weighing more than 20kg.